A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

NCT ID: NCT06698549

Last Updated: 2025-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-01
• Study Completion Date: 2025-07-21

Brief Summary

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.

Conditions

COVID 19

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Subjects with Severe Renal Impairment

Subjects with severe renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Subjects with Normal Renal Function

Subjects with normal renal function will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Subjects with Mild Renal Impairment (Optional)

Subjects with mild renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Subjects with Moderate Renal Impairment (Optional)

Subjects with moderate renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Interventions

ALG-097558

Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and Female between 18 and 75 years old

2. Body Mass Index (BMI) 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb)

3. Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective contraceptive therapy

1. Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs, clinical laboratory and 12-lead electrocardiogram (ECG) assessment

2. Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender

3. Normal renal function (estimated Glomerular Filtration Rate [eGFR] ≥90 mL/min) with no known or suspected renal impairment

1. Subject satisfies the eGFR criteria for renal impairment classification within 28 days of study drug administration

2. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).

3. Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening

4. Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria

Exclusion Criteria

1. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results and interpretation

2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant (subjects with normal renal function) or unstable (subjects with renal impairment) cardiac disease etc.

3. Subjects with a history of clinically significant drug allergy

4. Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use

5. Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men

6. Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up

7. Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection

8. Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >2x upper limit of normal (ULN)

9. Subjects with bilirubin (total, direct) >1.5x ULN (unless Gilbert's is suspected)

10. Positive pregnancy test; females must not be pregnant at enrollment

1. Hemoglobin <10 g/dL

1. Participants requiring hemodialysis and/or peritoneal dialysis

2. Hemoglobin <9 g/dL

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Aligos Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Miami

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Genesis Clinical Trials

Tampa, Florida, United States

Countries

United States

Other Identifiers

ALG-097558-703 / DMID 24-0022

Identifier Type: -

Identifier Source: org_study_id